Conference Coverage

New insights gained in PML risk stratification, detection, pathogenesis


 

FROM MSBOSTON 2014

References

Pages

Recommended Reading

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis. Report of the Guideline Development Subcommittee of the American Academy of Neurology
MDedge Neurology
Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Report of the Guideline Development Subcommittee of the American Academy of Neurology
MDedge Neurology
Older age at primary progressive MS onset predicted faster disability accumulation
MDedge Neurology
MS disability linked to abnormalities of spinal cord grey matter
MDedge Neurology
Peginterferon beta-1a approved for treating relapsing MS
MDedge Neurology
Clinical and Subclinical Factors Strongly Influence MS Treatment Decisions
MDedge Neurology
Alemtuzumab’s Benefits May Be Sustained for Three Years in Patients With MS
MDedge Neurology
Can Lesion Volume and Brain Atrophy Predict Outcomes in Early MS?
MDedge Neurology
Thalamic abnormalities lie at heart of cognitive impairment in MS
MDedge Neurology
Generic glatiramer acetate has similar safety, efficacy to Copaxone
MDedge Neurology